Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a Delaware corporation and emerging growth company, filed this Form 8-K on February 26, 2025. The filing reports the entry into a material definitive agreement regarding the amendment of a prior Securities Purchase Agreement (SPA) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial figures disclosed relate to the transaction terms:
- Transaction Payment: $75,000 paid by the Company to the Holder.
- Waived Rights: The Holder waived the right to purchase up to $10 million in Additional Notes and Additional Warrants.
- Historical Debt Context: The Holder was formerly the holder of a $4.3 million convertible note (the "Note").
- Warrant Holdings: The Holder retains a warrant to purchase 1,018,079 shares of common stock (127,260 post reverse split).
Material Changes
The primary material change is the execution of an Amendment Agreement on February 26, 2025, modifying the SPA originally dated January 11, 2023, and subsequently amended in May 2023, June 2023, and August 2024. Key changes include:
- Permanent waiver by the Holder of rights to acquire up to $10 million in additional debt and warrant instruments.
- A one-time waiver of the Holder's right to participate in the Company's contemplated registered securities offering (Form S-1 filed February 13, 2025).
Guidance, Outlook, and Risks
The filing references a contemplated registered securities offering disclosed in a Form S-1 filed on February 13, 2025. The amendment specifically removes the Holder's participation rights in this offering. No forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the transaction details are provided in this text. The filing notes that the description of the agreement is qualified by reference to the full text of the Amendment Agreement (Exhibit 10.1).
Investor Verification Checklist
- Verify the full terms of the Amendment Agreement attached as Exhibit 10.1.
- Review the Form S-1 (File No. 333-284889) filed on February 13, 2025, to understand the scope of the securities offering from which the Holder was excluded.
- Confirm the current status of the $4.3 million convertible note mentioned as formerly held by the investor.
- Assess the impact of the $75,000 cash outflow on the Company's current liquidity position.